ATE242317T1 - Verfahren zur reinigung von viren mit chromatographie - Google Patents

Verfahren zur reinigung von viren mit chromatographie

Info

Publication number
ATE242317T1
ATE242317T1 AT96924954T AT96924954T ATE242317T1 AT E242317 T1 ATE242317 T1 AT E242317T1 AT 96924954 T AT96924954 T AT 96924954T AT 96924954 T AT96924954 T AT 96924954T AT E242317 T1 ATE242317 T1 AT E242317T1
Authority
AT
Austria
Prior art keywords
pct
date
chromatography step
chromatography
viruses
Prior art date
Application number
AT96924954T
Other languages
English (en)
Inventor
Bernard Fanget
Alain Francon
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9481946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE242317(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE242317T1 publication Critical patent/ATE242317T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT96924954T 1995-08-10 1996-07-08 Verfahren zur reinigung von viren mit chromatographie ATE242317T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9509851A FR2737730B1 (fr) 1995-08-10 1995-08-10 Procede de purification de virus par chromatographie
PCT/FR1996/001064 WO1997006243A1 (fr) 1995-08-10 1996-07-08 Procede de purification de virus par chromatographie

Publications (1)

Publication Number Publication Date
ATE242317T1 true ATE242317T1 (de) 2003-06-15

Family

ID=9481946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96924954T ATE242317T1 (de) 1995-08-10 1996-07-08 Verfahren zur reinigung von viren mit chromatographie

Country Status (17)

Country Link
US (1) US6008036A (de)
EP (1) EP0848752B1 (de)
KR (1) KR100424337B1 (de)
CN (1) CN1090235C (de)
AT (1) ATE242317T1 (de)
AU (1) AU712490B2 (de)
BR (1) BR9609837A (de)
CA (1) CA2226312C (de)
DE (1) DE69628564T2 (de)
DK (1) DK0848752T3 (de)
EA (1) EA001414B1 (de)
ES (1) ES2197241T3 (de)
FR (1) FR2737730B1 (de)
MX (1) MX9801072A (de)
NZ (1) NZ313213A (de)
PT (1) PT848752E (de)
WO (1) WO1997006243A1 (de)

Families Citing this family (231)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2995542A1 (en) * 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP2942393A1 (de) 1998-09-04 2015-11-11 Genzyme Corporation Verfahren zur erzeugung helferfreier präparate mit hohem titer aus freigesetzten rekombinanten aav-vektoren
CA2364934C (fr) * 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6464976B1 (en) 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
EP1681299B1 (de) 2000-03-27 2009-11-11 Genetics Institute, LLC Verfahren zur Reinigung stark anionischer Proteine
EP1404428B1 (de) * 2001-06-05 2006-07-19 Genetics Institute, LLC Verfahren zur reinigung hochanionischer proteine
US6833238B2 (en) 2002-01-04 2004-12-21 Applera Corporation Petal-array support for use with microplates
US20040018559A1 (en) * 2002-07-26 2004-01-29 Applera Corporation Size-exclusion ion-exchange particles
CA2529053A1 (en) * 2003-06-18 2004-12-29 Onyx Pharmaceuticals, Inc. Method for purifying virus
AU2004249802B2 (en) * 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
US7479222B2 (en) * 2004-02-05 2009-01-20 Millipore Corporation Porous adsorptive or chromatographic media
US20050181378A1 (en) * 2004-02-18 2005-08-18 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20060160122A1 (en) * 2004-02-18 2006-07-20 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20050196856A1 (en) * 2004-02-18 2005-09-08 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
WO2005114171A2 (en) * 2004-05-20 2005-12-01 Chiron Srl Analysis of liquid chromatography eluates
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
PL2007883T3 (pl) 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
EP1878791A1 (de) * 2006-07-11 2008-01-16 Bia Separations D.O.O. Verfahren zur Reinigung von Influenzaviren
US9422342B2 (en) 2006-07-13 2016-08-23 Institute Of Advanced Study Recoding method that removes inhibitory sequences and improves HIV gene expression
US8481298B2 (en) 2006-09-29 2013-07-09 Ge Healthcare Bio-Sciences Ab Separation matrix for viral purification
WO2008067480A2 (en) 2006-11-29 2008-06-05 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
WO2010089339A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
FR2944292B1 (fr) * 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
EP4786482A2 (de) 2009-08-06 2026-08-05 F. Hoffmann-La Roche AG Virusfiltrierungsverfahren
EP2482825B1 (de) 2009-10-02 2016-11-23 The Trustees of Columbia University in the City of New York Diagnostische fisch-reoviren-zusammensetzungen
US8557253B2 (en) 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
WO2012015908A2 (en) 2010-07-30 2012-02-02 Millipore Corporation Chromatography media and method
DE102010046817A1 (de) 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
CA2816883A1 (en) 2010-11-23 2012-05-31 Presage Biosciences, Inc. Therapeutic methods and compositions for solid delivery
EP3495472B1 (de) 2011-04-21 2023-11-15 Nationwide Children's Hospital, Inc. Rekombinante virusprodukte und verfahren zur expressionshemmung von myotilin
US10196636B2 (en) 2011-04-21 2019-02-05 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
US20130039888A1 (en) 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
CA2842798C (en) 2011-07-25 2021-02-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
CA2880653C (en) 2012-08-01 2022-05-17 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
CA2885216A1 (en) 2012-09-17 2014-03-20 The Research Institute At Nationwide Children's Hospital Compositions and methods for treating amyotrophic lateral sclerosis
MY178616A (en) 2012-09-17 2020-10-19 Grace W R & Co Chromatography media and devices
JP6320429B2 (ja) * 2013-02-22 2018-05-09 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 負帯電粒子を用いるウイルス調製物のクロマトグラフィー精製
US9862945B2 (en) 2013-04-20 2018-01-09 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs
RS63942B1 (sr) 2013-08-27 2023-02-28 Res Inst Nationwide Childrens Hospital Proizvodi i postupci za lečenje amiotrofične lateralne skleroze
US9725719B2 (en) 2013-11-05 2017-08-08 The Research Institute At Nationwide Children's Hospital Compositions and methods for inhibiting NF-κB and SOD-1 to treat amyotrophic lateral sclerosis
IL230970A0 (en) 2014-02-13 2014-09-30 Univ Ramot Tilapia virus vaccines
US10047130B2 (en) 2014-03-18 2018-08-14 Washington University Methods and compositions for red-shifted chromophore substitution for optogenetic applications
CA2957661A1 (en) 2014-08-09 2016-02-18 Kevin FLANIGAN Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
EP3188816B1 (de) 2014-09-02 2021-06-09 EMD Millipore Corporation Chromatographie-medum, bestehend aus diskreten porösen bündeln von nanofibrillen
US10842886B2 (en) 2014-10-10 2020-11-24 Research Institute At Nationwide Children's Hospital Guided injections for AAV gene transfer to muscle
EP3690024A1 (de) 2014-11-05 2020-08-05 The Research Institute at Nationwide Children's Hospital Verfahren und materialien zur herstellung rekombinanter viren in eukaryotischen mikroalgen
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
US10183072B2 (en) 2014-12-15 2019-01-22 Kimron Veterinary Institute Tilapia virus and uses thereof
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
WO2016135558A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US10017832B2 (en) 2015-08-25 2018-07-10 Washington University Compositions and methods for site specific recombination at asymmetric sites
KR102799163B1 (ko) 2015-09-17 2025-04-21 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Galgt2 유전자 치료 방법 및 물질
WO2017064546A1 (en) 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
EP4279084B1 (de) 2015-10-28 2025-06-11 Vertex Pharmaceuticals Inc. Materialien und verfahren zur behandlung von duchenne-muskeldystrophie
US11866727B2 (en) 2015-11-06 2024-01-09 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1A
CN108463211B (zh) 2015-11-16 2022-09-27 全国儿童医院研究所 用于治疗肌联蛋白类肌病和其它肌联蛋白病变的材料和方法
WO2017093804A2 (en) 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
CA3009308A1 (en) 2015-12-23 2017-06-29 Chad Albert COWAN Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
US11938193B2 (en) 2016-01-08 2024-03-26 Washington University Compositions comprising chemerin and methods of use thereof
EP3411078A1 (de) 2016-02-02 2018-12-12 Crispr Therapeutics AG Materialien und verfahren zur behandlung von schwerer kombinierter immundefizienz (scid) oder omenn-syndrom
WO2017141109A1 (en) 2016-02-18 2017-08-24 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017147509A1 (en) 2016-02-25 2017-08-31 Marco Colonna Compositions comprising trem2 and methods of use thereof
JP6966463B2 (ja) 2016-02-26 2021-11-17 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 組換えウイルス産物及びｄｕｘ４エクソンスキッピングを誘導するための方法
US11083799B2 (en) 2016-03-16 2021-08-10 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
BR112018070249A2 (pt) 2016-04-02 2019-01-29 Research Institute At Nationwide Children's Hospital sistema promotor de u6 modificada para expressão específica de tecido
WO2017181011A1 (en) 2016-04-15 2017-10-19 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of microrna-29 to treat muscular dystrophy
CN109121395B (zh) 2016-04-15 2022-08-09 全国儿童医院研究所 腺相关病毒载体递送β-肌聚糖和微RNA-29以及肌营养不良症的治疗
JP6974349B2 (ja) 2016-04-18 2021-12-01 クリスパー セラピューティクス アクチェンゲゼルシャフト ヘモグロビン異常症の処置のための材料及び方法
WO2017191503A1 (en) 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
WO2018002762A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
CA3029119A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
EP3481857B1 (de) 2016-07-06 2026-02-11 Vertex Pharmaceuticals Incorporated Materialien und verfahren zur behandlung von schmerzbedingten erkrankungen
EP4650364A3 (de) 2016-07-06 2026-01-21 Vertex Pharmaceuticals Incorporated Materialien und verfahren zur behandlung von schmerzbedingten erkrankungen
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
US20190194628A1 (en) * 2016-09-01 2019-06-27 Takeda Vaccines, Inc. Methods for producing virus for vaccine production
IL322146A (en) 2016-11-17 2025-09-01 Nationwide Childrens Hospital Inc Intrathecal administration of adenovirus encoding methyl-CpG-binding protein 2
CA3045667A1 (en) 2016-12-13 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
WO2018154418A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
WO2018154439A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
EP3585899A1 (de) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materialien und verfahren zur behandlung von primärer hyperoxalurie typ 1 (ph1) und anderen mit dem alanin-glyoxylataminotransferase (agxt)-gen assoziierten erkrankungen oder störungen
WO2018154462A2 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
AU2018224387B2 (en) 2017-02-22 2024-08-08 Crispr Therapeutics Ag Compositions and methods for gene editing
EP3420076B1 (de) 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Verfahren zur herstellung und charakterisierung eines virusimpfstoffes und einer virenimpfstoffzusammensetzung
ES2975182T3 (es) 2017-03-06 2024-07-03 Guangzhou Realbenefitspot Pharmaceutical Co Ltd Métodos de producción y caracterización de vacunas víricas y composición de vacuna vírica
CN108524929B (zh) * 2017-03-06 2019-05-07 广州瑞贝斯药业有限公司 一种狂犬病疫苗的生产方法
CN110997923B (zh) 2017-03-17 2024-01-02 全国儿童医院研究所 腺相关病毒载体递送肌肉特异性微肌营养不良蛋白以治疗肌营养不良症
US11338045B2 (en) 2017-03-17 2022-05-24 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
RU2019133002A (ru) 2017-03-24 2021-04-26 Зе Юнивёрсити Корт Оф Зе Юнивёрсити Оф Эдинбург ЭКСПРЕССИОННЫЕ КАССЕТЫ MeCP2
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
WO2019011817A1 (en) 2017-07-08 2019-01-17 Genethon TREATMENT OF SPINAL AMYOTROPHY
MA49923A (fr) 2017-10-02 2020-06-24 Res Inst Nationwide Childrens Hospital Système de déciblage de miarn pour interférence spécifique d'un tissu
US20220080055A9 (en) 2017-10-17 2022-03-17 Crispr Therapeutics Ag Compositions and methods for gene editing for hemophilia a
WO2019078916A1 (en) 2017-10-18 2019-04-25 Research Institute At Nationwide Children's Hospital ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE-SPECIFIC MICRO-DYSTROPHINE TO TREAT MUSCLE DYSTROPHY
MX2020004035A (es) 2017-10-20 2020-11-09 Res Inst Nationwide Childrens Hospital Métodos y materiales para terapia génica con nt-3.
MA50849A (fr) 2017-10-26 2020-09-02 Vertex Pharma Substances et procédés pour le traitement d'hémoglobinopathies
EP4585229A3 (de) 2017-11-08 2026-01-14 Novartis AG Mittel und verfahren zur herstellung von viralen vektoren und deren verwendung
MA50579A (fr) 2017-11-09 2020-09-16 Crispr Therapeutics Ag Systèmes crispr/cas ou crispr/cpf1 à auto-inactivation (sin) et leurs utilisations
EP3714055A1 (de) 2017-11-21 2020-09-30 CRISPR Therapeutics AG Materialien und verfahren zur behandlung von autosomal-dominanter retinitis pigmentosa
CA3084825A1 (en) 2017-12-14 2019-06-20 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and their use in genome editing and other applications
CA3084633A1 (en) 2017-12-21 2019-06-27 Crispr Therapeutics Ag Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
AU2018393050A1 (en) 2017-12-21 2020-06-18 Bayer Healthcare Llc Materials and methods for treatment of Usher Syndrome Type 2A
EP3737762A1 (de) 2018-01-12 2020-11-18 CRISPR Therapeutics AG Zusammensetzungen und verfahren zur geneditierung von genen durch transferrin-targeting
AU2019216257B2 (en) 2018-01-31 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for limb-girdle muscular dystrophy type 2C
MA51787A (fr) 2018-02-05 2020-12-16 Vertex Pharma Substances et méthodes de traitement d'hémoglobinopathies
EP3749768A1 (de) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materialien und verfahren zur behandlung von hämoglobinopathien
EP3752616A1 (de) 2018-02-16 2020-12-23 CRISPR Therapeutics AG Zusammensetzungen und verfahren zur geneditierung durch targeting von fibrinogen-alpha
JP7550648B2 (ja) 2018-03-19 2024-09-13 クリスパー セラピューティクス アーゲー 新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
WO2019204668A1 (en) 2018-04-18 2019-10-24 Casebia Therapeutics Limited Liability Partnership Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
CA3091490A1 (en) 2018-04-27 2019-10-31 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
JP7478675B2 (ja) 2018-06-08 2024-05-07 ノバルティス アーゲー 薬物製品の効力を測定するための細胞ベースアッセイ
GB201809588D0 (en) 2018-06-12 2018-07-25 Univ Bristol Materials and methods for modulating intraocular and intracranial pressure
JP7534961B2 (ja) 2018-06-18 2024-08-15 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法
IL324506A (en) 2018-06-18 2026-01-01 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector for delivery of muscle-specific microdystrophin for the treatment of muscular dystrophy
IL279789B2 (en) 2018-06-29 2026-04-01 Res Inst Nationwide Childrens Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
AU2019326551A1 (en) 2018-08-22 2021-03-18 Research Institute At Nationwide Children's Hospital Recombinant virus products and methods for inhibiting expression of dystrophia myotonica protein kinase and/or interfering with a trinucleotide repeat expansion in the 3' untranslated region of the DMPK gene
AU2019328270B2 (en) 2018-08-29 2026-02-26 Research Institute At Nationwide Children's Hospital Products and methods for inhibition of expression of mutant GARS protein
JP7520826B2 (ja) 2018-10-17 2024-07-23 クリスパー・セラピューティクス・アクチェンゲゼルシャフト 導入遺伝子を送達するための組成物および方法
CA3121191A1 (en) 2018-11-28 2020-06-04 Crispr Therapeutics Ag Optimized mrna encoding cas9 for use in lnps
EP3886919A1 (de) 2018-11-30 2021-10-06 Novartis AG Aav-virusvektoren und verwendungen davon
US20220042045A1 (en) 2018-12-21 2022-02-10 Genethon Expression cassettes for gene therapy vectors
JP2022516515A (ja) 2018-12-31 2022-02-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｒｎａ標的化ｃｒｉｓｐｒ－ｃａｓ１３ｂを使用するｄｕｘ４ ｒｎａ発現停止
TW202600150A (zh) 2019-01-25 2026-01-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
AR118005A1 (es) 2019-02-04 2021-09-08 Res Institute At Nationwide Children’S Hospital Administración del virus adenoasociado de polinucleótido de cln3
AU2020218501B2 (en) 2019-02-04 2026-01-29 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery of CLN6 polynucleotide
SG11202108357PA (en) 2019-02-15 2021-08-30 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
KR20210133242A (ko) 2019-02-26 2021-11-05 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 B-사르코글리칸의 아데노 관련 바이러스 벡터 전달 및 근이영양증의 치료
US20220145274A1 (en) 2019-03-12 2022-05-12 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
US20220193259A1 (en) 2019-04-15 2022-06-23 Sanford Research Gene therapy for treating or preventing visual effects in batten disease
EP3966327A1 (de) 2019-05-08 2022-03-16 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two-vektorsystemen zur behandlung von dmd
JP7707081B2 (ja) 2019-05-17 2025-07-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 網膜細胞を標的とした最適化された遺伝子治療
US12173290B2 (en) 2019-06-28 2024-12-24 Crispr Therapeutics Ag Materials and methods for controlling gene editing
CN114174514A (zh) 2019-07-25 2022-03-11 诺华股份有限公司 可调节的表达系统
CA3150964A1 (en) 2019-08-21 2021-02-25 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
JP7781057B2 (ja) 2019-10-18 2025-12-05 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｉｒｆ２ｂｐｌ遺伝子の変異に関連する障害の治療のための材料および方法
AU2020366531A1 (en) 2019-10-18 2022-05-26 Research Institute At Nationwide Children's Hospital Gene therapy targeting cochlear cells
US20230211018A1 (en) 2019-11-22 2023-07-06 Research Institute At Nationwide Children's Hospital Materials and methods for treatment of disorders associated with the ighmbp2 gene
EP4077687A1 (de) 2019-12-20 2022-10-26 Research Institute at Nationwide Children's Hospital Optimierte gentherapie zum targeting von muskeln bei muskelerkrankungen
WO2021168124A1 (en) 2020-02-18 2021-08-26 Research Institute At Nationwide Children's Hospital Aav-mediated targeting of mirna in the treatment of x-linked disorders
CN115379863A (zh) 2020-04-14 2022-11-22 吉尼松公司 用于治疗酸性神经酰胺酶缺乏症的载体
EP4164668A1 (de) 2020-06-15 2023-04-19 Research Institute at Nationwide Children's Hospital Adeno-assoziierte virusvektorverabreichung für muskeldystrophien
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
TWI887479B (zh) 2020-09-08 2025-06-21 美商薩羅塔治療公司 表現γ-肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
CN114181970B (zh) * 2020-09-15 2023-07-25 上海药明巨诺生物医药研发有限公司 一种慢病毒载体纯化方法
JP2023541444A (ja) 2020-09-15 2023-10-02 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィー患者における多様なｄｍｄ変異の補正のためのａａｖ媒介性の相同性非依存的標的化組み込み遺伝子編集
US20240261434A1 (en) 2020-09-28 2024-08-08 Research Institute At Nationwide Children's Hospital Products and methods for treating muscular dystrophy
WO2022070107A1 (en) 2020-09-30 2022-04-07 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis
RU2748475C1 (ru) * 2020-11-02 2021-05-26 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Способ спектрометрического определения концентрации рибонуклеопротеина вируса бешенства по оценке количества молекул вирусной РНК в сырье для антирабических вакцин
CA3203585A1 (en) 2020-11-30 2022-06-02 Research Institute At Nationwide Children's Hospital Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
EP4263829A1 (de) 2020-12-17 2023-10-25 Vertex Pharmaceuticals Incorporated Zusammensetzungen und verfahren zur bearbeitung von beta-globin zur behandlung von hämglobinopathien
WO2022164860A1 (en) 2021-01-27 2022-08-04 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
US20240093191A1 (en) 2021-02-03 2024-03-21 Research Institute At Nationwide Children's Hospital Compositions and methods for treating disease associated with dux4 overexpression
WO2022170038A1 (en) 2021-02-05 2022-08-11 Amicus Therapeutics, Inc. Adeno-associated virus delivery of cln3 polynucleotide
EP4301462A1 (de) 2021-03-04 2024-01-10 Research Institute at Nationwide Children's Hospital Produkte und verfahren zur behandlung von dystrophinbasierten myopathien mit crispr-cas9 zur korrektur von dmd-exon-duplikationen
CN115427561B (zh) 2021-03-09 2024-06-04 辉大(上海)生物科技有限公司 工程化CRISPR/Cas13系统及其用途
WO2022221424A1 (en) 2021-04-13 2022-10-20 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery
US12275941B2 (en) 2021-04-15 2025-04-15 Research Institute At Nationwide Children's Hospital Products and methods for inhibition of expression of dynamin-1 variants
AU2022262420A1 (en) 2021-04-23 2023-11-16 Research Institute At Nationwide Children's Hospital Products and methods for treating muscular dystrophy
BR112023024078A2 (pt) 2021-05-17 2024-01-30 Sarepta Therapeutics Inc Produção de vetores de aav recombinantes para o tratamento de distrofia muscular
EP4108263A3 (de) 2021-06-02 2023-03-22 Research Institute at Nationwide Children's Hospital Rekombinante adeno-assoziierte virusprodukte und verfahren zur behandlung von gliedergürtel-muskeldystrophie 2a
EP4101928A1 (de) 2021-06-11 2022-12-14 Bayer AG Programmierbare typ-v-rna-endonukleasesysteme
MX2023014774A (es) 2021-06-11 2024-01-15 Bayer Ag Nuevos sistemas de endonucleasas programables de arn tipo v.
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
CA3228365A1 (en) 2021-08-11 2023-02-16 Solid Biosciences Inc. Treatment of muscular dystrophy
EP4144841A1 (de) 2021-09-07 2023-03-08 Bayer AG Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
JP2024534410A (ja) 2021-09-16 2024-09-20 ノバルティス アーゲー 新規転写因子
US20240401046A1 (en) 2021-10-07 2024-12-05 Research Institute At Nationwide Children' S Hospital Products and methods for myelin protein zero silencing and treating cmt1b disease
WO2023060233A1 (en) 2021-10-08 2023-04-13 Amicus Therapeutics, Inc. Biomarkers for lysosomal storage diseases
US12285497B2 (en) 2021-10-15 2025-04-29 Research Institute At Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
AU2022386664A1 (en) 2021-11-12 2024-06-13 Research Institute At Nationwide Children's Hospital Materials and methods for slc6a1 gene therapy
US20230279431A1 (en) 2021-11-30 2023-09-07 Research Institute At Nationwide Children's Hospital Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy
EP4198046A1 (de) 2021-12-16 2023-06-21 Genethon Erhöhung des gentransfers von alpha-sarcoglykan unter verwendung von modifizierten itr-sequenzen
EP4198134A1 (de) 2021-12-16 2023-06-21 Genethon Transfererhöhung des gamma-sarcoglycan-gens unter verwendung von modifizierten itr-sequenzen
EP4198048A1 (de) 2021-12-16 2023-06-21 Genethon Calpain-3-gentransfersteigerung unter verwendung von modifizierten itr-sequenzen
EP4198047A1 (de) 2021-12-16 2023-06-21 Genethon Erhöhung des gentransfers von fukutin-verwandtem protein unter verwendung modifizierter itr-sequenzen
EP4453013A1 (de) 2021-12-21 2024-10-30 Research Institute at Nationwide Children's Hospital Materialien und verfahren zur behandlung von muskeldystrophie bei gliedmassengürteln
EP4453191A1 (de) 2021-12-23 2024-10-30 Bayer Aktiengesellschaft Neuartige programmierbare endonukleasesysteme für kleine v-rna
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023168400A2 (en) 2022-03-03 2023-09-07 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
AU2023250649A1 (en) 2022-04-04 2024-11-14 The Regents Of The University Of California Genetic complementation compositions and methods
CA3255627A1 (en) 2022-05-06 2023-11-09 Novartis Ag NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
JP2025523399A (ja) 2022-06-08 2025-07-23 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 変異型又は病原性ｋｃｎｑ３発現に関連する疾患又は状態を治療するための生成物及び方法
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
AU2023303015A1 (en) 2022-07-06 2025-01-23 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery of cln1 polynucleotide
WO2024035782A1 (en) 2022-08-10 2024-02-15 Aav Gene Therapeutics, Inc. Aav-mediated intramuscular delivery of insulin
WO2024081706A1 (en) 2022-10-11 2024-04-18 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
EP4608856A1 (de) 2022-10-27 2025-09-03 CARGO Therapeutics, Inc. Zusammensetzungen und verfahren für verbesserte immuntherapien
CN120569476A (zh) 2022-11-30 2025-08-29 安铂生物公司 用于靶向反式剪接的方法和组合物
US20260209732A1 (en) 2022-12-13 2026-07-23 Bayer Aktiengesellschaft Engineered type v rna programmable endonucleases and their uses
US20260216373A1 (en) 2023-01-13 2026-07-30 Amicus Therapeutics, Inc. Gene Therapy Constructs for the Treatment of Pompe Disease
KR20250138783A (ko) 2023-02-01 2025-09-22 사렙타 쎄러퓨틱스 인코퍼레이티드 rAAV 생산 방법
WO2024168276A2 (en) 2023-02-09 2024-08-15 Cargo Therapeutics, Inc. Compositions and methods for immunotherapies
JP2026516715A (ja) 2023-04-18 2026-05-26 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 肢帯型筋ジストロフィーｒ９及び先天性筋ジストロフィー１ｃを治療するための遺伝子療法
WO2024229115A1 (en) 2023-05-02 2024-11-07 Research Institute At Nationwide Children's Hospital Treatment of multiple sclerosis using nt-3 gene therapy
AU2024265705A1 (en) 2023-05-02 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for treatment of protein misfolding diseases
AU2024265701A1 (en) 2023-05-02 2025-12-04 Research Institute At Nationwide Children's Hospital A modular system to convert therapeutic microrna expression cassettes from polymerase iii-based to polymerase ii-based promoters
WO2024254319A1 (en) 2023-06-07 2024-12-12 Research Institute At Nationwide Children's Hospital Gene therapy for lysosomal acid lipase deficiency (lal-d)
EP4727966A1 (de) 2023-06-13 2026-04-22 Research Institute at Nationwide Children's Hospital Materialien und verfahren zur behandlung von neurofibromin-1-mutationen und daraus resultierende erkrankungen
CN116718524B (zh) * 2023-06-26 2025-11-07 西安交通大学 一种基于细胞膜色谱技术的病毒颗粒检测方法
WO2025022290A1 (en) 2023-07-21 2025-01-30 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
EP4512403A1 (de) 2023-08-22 2025-02-26 Friedrich-Schiller-Universität Jena Neuropeptid b und w-rezeptor als ziel zur behandlung von stimmungsstörungen und/oder chronischem stress
TW202521691A (zh) 2023-10-06 2025-06-01 美商藍岩醫療公司 經工程化之v型rna可程式核酸內切酶及其用途
WO2025096498A1 (en) 2023-10-30 2025-05-08 Research Institute At Nationwide Children's Hospital Compositions and methods for treating diseases or conditions associated with progerin expression
US12655424B2 (en) 2024-02-05 2026-06-16 Amber Bio Inc. Methods and compositions for trans-splicing utilizing small nuclear RNAs and small nucleolar RNAs
WO2025179121A1 (en) 2024-02-21 2025-08-28 Research Institute At Nationwide Children's Hospital Exon 17-targeted nucleic acids, compositions, and methods for treatment of dystrophin-based myopathies
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025188993A2 (en) 2024-03-07 2025-09-12 Research Institute At Nationwide Children's Hospital Gene therapy for treating gne-related disorders
WO2025212838A1 (en) 2024-04-03 2025-10-09 Research Institute At Nationwide Children's Hospital Products and methods for treating diseases or disorders associated with dux4 overexpression
WO2025226343A1 (en) 2024-04-26 2025-10-30 Research Institute At Nationwide Children's Hospital Products and methods to inhibit expression of dynamin-1 variants and replace dynamin-1
WO2025235425A1 (en) 2024-05-06 2025-11-13 Research Institute At Nationwide Children's Hospital Improved proviral plasmids
WO2025240690A2 (en) 2024-05-15 2025-11-20 Research Institute At Nationwide Children's Hospital Products and methods for treating diseases or conditions associated with progerin expression from an aberrant lmna gene
TW202613313A (zh) 2024-05-31 2026-04-01 美商薩羅塔治療公司 肌向性ｒａａｖ
WO2026028089A1 (en) 2024-07-29 2026-02-05 Novartis Ag Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
WO2026094009A1 (en) 2024-11-04 2026-05-07 Insmed Incorporated Compositions and methods for treating duchenne muscular dystrophy
WO2026107323A1 (en) 2024-11-15 2026-05-21 Research Institute At Nationwide Children's Hospital Products and methods for full-length smchd1 expression using split inteins
WO2026150302A1 (en) 2025-01-09 2026-07-16 Novartis Ag Novel aav rep/cap encoding constructs
WO2026150324A1 (en) 2025-01-10 2026-07-16 Sarepta Therapeutics, Inc. Compositions and methods for treating dysferlinopathies
US12686869B1 (en) 2026-01-23 2026-07-21 Amber Bio Inc. Methods and compositions for trans-splicing utilizing trifunctional elements

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1441767A (fr) * 1965-04-30 1966-06-10 Rohm & Haas élimination des virus au cours des processus de collecte ou de transfusion du sang
US4162192A (en) * 1978-09-28 1979-07-24 Juridical Foundation Method for purification of HBs antigen
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
WO1995001797A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation Protein purification
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors

Also Published As

Publication number Publication date
AU6496496A (en) 1997-03-05
CA2226312A1 (fr) 1997-02-20
FR2737730A1 (fr) 1997-02-14
WO1997006243A1 (fr) 1997-02-20
US6008036A (en) 1999-12-28
EP0848752A1 (de) 1998-06-24
BR9609837A (pt) 1999-03-09
CA2226312C (fr) 2011-11-08
NZ313213A (en) 1999-03-29
KR100424337B1 (ko) 2004-06-24
DE69628564T2 (de) 2004-05-13
DK0848752T3 (da) 2003-09-29
CN1090235C (zh) 2002-09-04
EA001414B1 (ru) 2001-02-26
CN1199419A (zh) 1998-11-18
FR2737730B1 (fr) 1997-09-05
KR19990036328A (ko) 1999-05-25
MX9801072A (es) 1998-04-30
EA199800159A1 (ru) 1998-08-27
DE69628564D1 (de) 2003-07-10
ES2197241T3 (es) 2004-01-01
PT848752E (pt) 2003-10-31
AU712490B2 (en) 1999-11-11
EP0848752B1 (de) 2003-06-04

Similar Documents

Publication Publication Date Title
DE69628564D1 (de) Verfahren zur reinigung von viren mit chromatographie
DE69525408D1 (de) System zur prüfung von nachrichtenübertragungsleitungen
DE69412827D1 (de) Niedrigdruckverfahren zur hydrierung von dimethylbenzoldicarboxylaten zu den entsprechenden dimethylcyclohexancarboxylaten
DE69008315D1 (de) Verfahren zur Steuerung eines Wechselrichters.
DE69707849D1 (de) Verfahren zur reinigung von 1,4-butandiol
ATE179986T1 (de) Verfahren zur herstellung von 1-(2'-deoxy-2',2'- difluoro-d-ribofuranosyl)-4-amino-pyrimidin-2-o - hydrochlorid
EP0765508A4 (de) System und verfahren zur verbesserung von graphischen merkmalen von markierungsgeräten
ATE343175T1 (de) Dateitransfersystem, vorrichtung, verfahren und computerlesbares medium, das ein dateitransferprogramm speichert
TR199501122A2 (tr) Etil alkol üretim yöntemi.
ATE118498T1 (de) Verfahren zur reinigung von n- phosphonmethylglyzin.
IL122606A (en) (S)-hydroxa-nitrile-lyase
DE59009031D1 (de) Vorrichtung zur reduzierung von leerlaufverlusten bei hydrodynamischen bremsen.
ATE212980T1 (de) Verfahren zur reinigung von dimethylsulfoxyd (dmso)
CA2058958A1 (en) Method of cleansing proteins
DE69432706D1 (de) Verfahren zur reinigung von "basic" fibroblasten wachstumsfaktor
DE69610421D1 (de) Verfahren zur herstellung von alpha,beta-ungesättigten nitrilen
DE59001866D1 (de) Verfahren zur biologischen abwasserbehandlung mit hilfe von mikroorganismen.
DE69405023D1 (de) Verfahren zur Herstellung wässriger Nicotinaldehyde
MX9602901A (es) Aparato de transferencia de calor con intercambio de calor con generador-absorcion y metodo que usa un licor intermedio y el uso del mismo en una bomba de calor de absorcion.
PT828486E (pt) Utilizacao de derivados de pirrolidina no tratamento do alcoolismo
ATE181838T1 (de) Verfahren zur mikrobiologischen dekontaminierung von blutplättchen
DE3863411D1 (de) Verfahren zur reinigung von wasserstoff.
DE59506919D1 (de) Verfahren zur herstellung von aliphatischen alpha,omega-aminonitrilen
DE59611353D1 (de) Transketolase-verwandtes protein
DE69521857D1 (de) Verfahren zur herstellung von optisch aktiven 2-aryl-3-acyloxy-1,2-propandiolen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0848752

Country of ref document: EP

REN Ceased due to non-payment of the annual fee